ABSTRACT This retrospective analysis investigated the prognostic value of del(13) and t(4;14) abnormalities and the impact of prior treatment on outcomes in 207 heavily pretreated patients

with relapsed or refractory multiple myeloma (MM) treated with lenalidomide plus dexamethasone. Patients with relapsed or refractory MM who had either earlier received thalidomide or

bortezomib, or for whom continuation of these agents was contraindicated, and who had fluorescence _in situ_ hybridization data available were included in the analysis. Patients with

relapsed or refractory MM who received treatment with lenalidomide plus dexamethasone in the presence of del(13) and t(4;14) chromosomal abnormalities had lower overall response rates (ORRs)

hemoglobin levels <10 g per 100 ml were prognostic factors for ORR and PFS, but not OS, in these heavily pretreated relapsed or refractory MM patients treated with lenalidomide plus

dexamethasone. Access through your institution Buy or subscribe This is a preview of subscription content, access via your institution ACCESS OPTIONS Access through your institution

Subscribe to this journal Receive 12 print issues and online access $259.00 per year only $21.58 per issue Learn more Buy this article * Purchase on SpringerLink * Instant access to full

article PDF Buy now Prices may be subject to local taxes which are calculated during checkout ADDITIONAL ACCESS OPTIONS: * Log in * Learn about institutional subscriptions * Read our FAQs *

Contact customer support SIMILAR CONTENT BEING VIEWED BY OTHERS DARATUMUMAB, LENALIDOMIDE, AND DEXAMETHASONE IN RELAPSED/REFRACTORY MYELOMA: A CYTOGENETIC SUBGROUP ANALYSIS OF POLLUX Article

Open access 03 November 2020 A POOLED ANALYSIS OF OUTCOMES ACCORDING TO CYTOGENETIC ABNORMALITIES IN PATIENTS RECEIVING IXAZOMIB- VS PLACEBO-BASED THERAPY FOR MULTIPLE MYELOMA Article Open

access 12 January 2023 DARATUMUMAB-BASED QUADRUPLET THERAPY FOR TRANSPLANT-ELIGIBLE NEWLY DIAGNOSED MULTIPLE MYELOMA WITH HIGH CYTOGENETIC RISK Article Open access 22 April 2024 REFERENCES *

Jemal A, Siegel R, Ward E, Hao Y, Xu J, Murray T _et al_. Cancer statistics, 2008. _CA Cancer J Clin_ 2008; 58: 71–96. Article  Google Scholar  * Sirohi B, Powles R . Epidemiology and

outcomes research for MGUS, myeloma and amyloidosis. _Eur J Cancer_ 2006; 42: 1671–1683. Article  Google Scholar  * Dimopoulos M, Spencer A, Attal M, Prince HM, Harousseau JL, Dmoszynska A

_et al_. Multiple Myeloma (010) Study Investigators. Lenalidomide plus dexamethasone for relapsed or refractory multiple myeloma. _N Engl J Med_ 2007; 357: 2123–2132. Article  CAS  Google

Scholar  * Weber DM, Chen C, Niesvizky R, Wang M, Belch A, Stadtmauer EA _et al_. Multiple Myeloma (009) Study Investigators. Lenalidomide plus dexamethasone for relapsed multiple myeloma in

North America. _N Engl J Med_ 2007; 357: 2133–2142. Article  CAS  Google Scholar  * Fonseca R, Blood E, Rue M, Harrington D, Oken MM, Kyle RA _et al_. Clinical and biological implications

of recurrent genomic aberrations in myeloma. _Blood_ 2003; 101: 4569–4575. Article  CAS  Google Scholar  * Avet-Loiseau H, Attal M, Moreau P, Charbonnel C, Garban F, Hulin C _et al_. Genetic

abnormalities and survival in multiple myeloma: the experience of the Intergroupe Francophone du Myélome. _Blood_ 2007; 109: 3489–3495. CAS  Google Scholar  * Gertz MA, Lacy MQ, Dispenzieri

A, Greipp PR, Litzow MR, Henderson KJ _et al_. Clinical implications of t(11;14)(q13;q32), t(4;14)(p16.3;q32), and -17p13 in myeloma patients treated with high-dose therapy. _Blood_ 2005;

106: 2837–2840. Article  CAS  Google Scholar  * Debes-Marun CS, Dewald GW, Bryant S, Picken E, Santana-Davila R, Gonzalez-Paz N _et al_. Chromosome abnormalities clustering and its

implications for pathogenesis and prognosis in myeloma. _Leukemia_ 2003; 17: 427–436. CAS  Google Scholar  * Zonder JA, Crowley JJ, Bolejack V, Hussein MA, Moore DF, Whittenberger BF _et

al_. A randomized Southwest Oncology Group study comparing dexamethasone (D) to lenalidomide + dexamethasone (LD) as treatment of newly-diagnosed multiple myeloma (NDMM): impact of

cytogenetic abnormalities on efficacy of LD, and updated overall study results. _J Clin Oncol_ 2008; 26. [Abstract 8521]. Article  Google Scholar  * Reece D, Song KW, Fu T, Roland B, Chang

H, Horsman DE _et al_. Influence of cytogenetics in patients with relapsed or refractory multiple myeloma treated with lenalidomide plus dexamethasone: adverse effect of deletion 17p13.

_Blood_ 2009; 114: 522–525. Article  CAS  Google Scholar  * Kapoor P, Kumar S, Fonseca R, Lacy MQ, Witzig TE, Hayman SR _et al_. Impact of risk stratification on outcome among patients with

multiple myeloma receiving initial therapy with lenalidomide and dexamethasone. _Blood_ 2009; 114: 518–521. Article  CAS  Google Scholar  * Bladé J, Samson D, Reece D, Apperley J,

Björkstrand B, Gahrton G _et al_. Criteria for evaluating disease response and progression in patients with multiple myeloma treated by high-dose therapy and haemopoietic stem cell

transplantation. Myeloma Subcommittee of the EBMT. European Group for Blood and Marrow Transplant. _Br J Haematol_ 1998; 102: 1115–1123. Article  Google Scholar  * Stadtmauer EA, Weber DM,

Niesvizky R, Belch A, Prince MH, San Miguel JF _et al_. Lenalidomide in combination with dexamethasone at first relapse in comparison with its use as later salvage therapy in relapsed or

refractory multiple myeloma. _Eur J Haematol_ 2009; 82: 426–432. Article  CAS  Google Scholar  * Wang M, Dimopoulos MA, Chen C, Cibeira MT, Attal M, Spencer A _et al_. Lenalidomide plus

dexamethasone is more effective than dexamethasone alone in patients with relapsed or refractory multiple myeloma regardless of prior thalidomide exposure. _Blood_ 2008; 112: 4445–4451.

Article  CAS  Google Scholar  * Naujokat C, Fuchs D, Berges C . Adaptive modification and flexibility of the proteasome system in response to proteasome inhibition. _Biochim Biophys Acta_

2007; 1773: 1389–1397. Article  CAS  Google Scholar  * Fuchs D, Berges C, Opelz G, Daniel V, Naujokat C . Increased expression and altered subunit composition of proteasomes induced by

continuous proteasome inhibition establish apoptosis resistance and hyperproliferation of Burkitt lymphoma cells. _J Cell Biochem_ 2008; 103: 270–283. Article  CAS  Google Scholar  *

Sagaster V, Ludwig H, Kaufmann H, Odelga V, Zojer N, Ackermann J _et al_. Bortezomib in relapsed multiple myeloma: response rates and duration of response are independent of a chromosome

13q-deletion. _Leukemia_ 2007; 21: 164–168. Article  CAS  Google Scholar  * Jagannath S, Richardson PG, Sonneveld P, Schuster MW, Irwin D, Stadtmauer EA _et al_. Bortezomib appears to

overcome the poor prognosis conferred by chromosome 13 deletion in phase 2 and 3 trials. _Leukemia_ 2007; 21: 151–157. Article  CAS  Google Scholar  Download references AUTHOR INFORMATION

AUTHORS AND AFFILIATIONS * Institut National de la Santé et de la Recherche Médicale (INSERM), Unité 892, Nantes, France H Avet-Loiseau, S Minvielle & P Moreau * Hematology Laboratory,

University Hospital Hôtel-Dieu, Nantes, France H Avet-Loiseau & S Minvielle * Centre d’Etude et de Recherche sur le Myélome (CERM), Nantes, France H Avet-Loiseau, S Minvielle & P

Moreau * Institut Régional du Cancer Nantes-Atlantique (IRCNA), Nantes, France H Avet-Loiseau, S Minvielle & P Moreau * Institut Universitaire d’Hématologie (IUH), Université Denis

Diderot, Hematology Laboratory AP-HP, Hôpital St-Louis, Paris, France J Soulier & J-P Fermand * Département d’Immunologie, Hôpital Saint-Louis, Assistance Publique-Hôpitaux de Paris,

Paris, France J-P Fermand * Hematology Department, University Hospital Huriez, Lille, France I Yakoub-Agha * Hematology Department, Centre Hospitalier Purpan, Toulouse, France M Attal *

Hematology Department, University Hospital Brabois, Nancy, France C Hulin * Hematology Department, Hôpital Saint-Antoine, Assistance Publique-Hôpitaux de Paris, Paris, France L Garderet *

Hematology Department, Hôpital Henri Mondor, Assistance Publique-Hôpitaux de Paris, Paris, France K Belhadj * Hematology Department, Hôpital Notre-Dame de Bon Secours, Metz, France V Dorvaux

* Hematology Department, University Hospital Hôtel-Dieu, Nantes, France P Moreau Authors * H Avet-Loiseau View author publications You can also search for this author inPubMed Google

Scholar * J Soulier View author publications You can also search for this author inPubMed Google Scholar * J-P Fermand View author publications You can also search for this author inPubMed 

Google Scholar * I Yakoub-Agha View author publications You can also search for this author inPubMed Google Scholar * M Attal View author publications You can also search for this author

inPubMed Google Scholar * C Hulin View author publications You can also search for this author inPubMed Google Scholar * L Garderet View author publications You can also search for this

author inPubMed Google Scholar * K Belhadj View author publications You can also search for this author inPubMed Google Scholar * V Dorvaux View author publications You can also search for

this author inPubMed Google Scholar * S Minvielle View author publications You can also search for this author inPubMed Google Scholar * P Moreau View author publications You can also search

for this author inPubMed Google Scholar CONSORTIA FOR THE IFM AND MAG GROUPS CORRESPONDING AUTHOR Correspondence to H Avet-Loiseau. RIGHTS AND PERMISSIONS Reprints and permissions ABOUT

THIS ARTICLE CITE THIS ARTICLE Avet-Loiseau, H., Soulier, J., Fermand, JP. _et al._ Impact of high-risk cytogenetics and prior therapy on outcomes in patients with advanced relapsed or

refractory multiple myeloma treated with lenalidomide plus dexaméthasone. _Leukemia_ 24, 623–628 (2010). https://doi.org/10.1038/leu.2009.273 Download citation * Received: 06 May 2009 *

Revised: 29 October 2009 * Accepted: 09 November 2009 * Published: 14 January 2010 * Issue Date: March 2010 * DOI: https://doi.org/10.1038/leu.2009.273 SHARE THIS ARTICLE Anyone you share

the following link with will be able to read this content: Get shareable link Sorry, a shareable link is not currently available for this article. Copy to clipboard Provided by the Springer

Nature SharedIt content-sharing initiative KEYWORDS * myeloma * lenalidomide * cytogenetics * FISH * prognosis